An executive conversation on why workplace inclusion is an outcome to strive for.

President and CEO, Florida Blue
Former CEO, Health Evolution
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Diversity as a Strategic Priority

How can your I&D goals thrive? Walk the talk, says Florida Blue's CEO.

President and CEO, Florida Blue
Former CEO, Health Evolution
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

2018 was a big year for industry news. Here's what might happen next in artificial intelligence, the 2020 presidential election, pharma, and more.

Partner, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Our interviews and research unearth the visible and invisible forces contributing to healthcare's gender leadership gap.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

What it's like to be the only female leader in the room, and how digital innovation is advancing SDoH.

Professor of Medicine and Population Health, The University of Texas at Austin Dell Medical School
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Insights in your inbox

Subscribe

In the wake of disruption from industries like retail and finance, healthcare incumbents must anticipate disruption from the side or above, not just head-on.

Chief Strategy Officer, BCBS of Massachusetts
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

In this video, Terry Stone discusses where disruptive innovation is likely to come from and why.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

According to Oliver Wyman’s Consumer Survey of US Healthcare, women are more engaged in their health decisions than men. Healthcare companies must give female consumers the kind of health system they're seeking.

Chief Strategy Officer, BCBS of Massachusetts
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Engagement Manager, Health & Life Sciences, Oliver Wyman

2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.

Partner, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Insights in your inbox

Subscribe
Load More